Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rostam Namdari

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacology|July 1, 2006
Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patientsAgop Y Bedikian, Anna Vardeleon, Teresa Smith, et al.
Neurology and Therapy|April 5, 2022
Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 TrialRostam Namdari, Constanza Luzon, Jay A Cadieux, et al.
Pain|January 18, 2014
Letter to the editorYigal Paul Goldberg, Charles J Cohen, Rostam Namdari, et al.
The Clinical Journal of Pain|March 8, 2017
Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W GenotypeNicola Price, Rostam Namdari, Judith Neville, et al.
Pain|November 1, 2011
Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blockerYigal Paul Goldberg, Nicola Price, Rostam Namdari, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2013
Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effectsShaoyi Sun, Zaihui Zhang, Vandna Raina, et al.
JAMA Network Open|May 27, 2025
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical TrialNoam N Butterfield, Constanza Luzon Rosenblut, Maurizio Fava, et al.
Regulatory Toxicology and Pharmacology : RTP|August 29, 2021
Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practiceRostam Namdari, Keith Jones, Samuel S Chuang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 2023
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety EvaluationAlison Cutts, Sultan Chowdhury, Laszlo G Ratkay, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacology|July 1, 2006
Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patientsAgop Y Bedikian, Anna Vardeleon, Teresa Smith, et al.
Neurology and Therapy|April 5, 2022
Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 TrialRostam Namdari, Constanza Luzon, Jay A Cadieux, et al.
Pain|January 18, 2014
Letter to the editorYigal Paul Goldberg, Charles J Cohen, Rostam Namdari, et al.
The Clinical Journal of Pain|March 8, 2017
Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W GenotypeNicola Price, Rostam Namdari, Judith Neville, et al.
Pain|November 1, 2011
Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blockerYigal Paul Goldberg, Nicola Price, Rostam Namdari, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2013
Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effectsShaoyi Sun, Zaihui Zhang, Vandna Raina, et al.
JAMA Network Open|May 27, 2025
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical TrialNoam N Butterfield, Constanza Luzon Rosenblut, Maurizio Fava, et al.
Regulatory Toxicology and Pharmacology : RTP|August 29, 2021
Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practiceRostam Namdari, Keith Jones, Samuel S Chuang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 2023
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety EvaluationAlison Cutts, Sultan Chowdhury, Laszlo G Ratkay, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 1